What is Enanta Pharmaceuticals's market cap?

Enanta Pharmaceuticals (ENTA) has a market capitalization of $370.2M and trades on NASDAQ.

Who are Enanta Pharmaceuticals's competitors?

Enanta Pharmaceuticals's key competitors include Gilead Sciences, Inc., Merck & Co., Inc., Regeneron Pharmaceuticals, Inc., and others. These companies compete in similar markets and product categories.

Who does Enanta Pharmaceuticals partner with?

Enanta Pharmaceuticals's notable partners include AbbVie Inc., OMERS, AstraZeneca, and others.

Where is Enanta Pharmaceuticals headquartered?

Enanta Pharmaceuticals is headquartered in United States of America and employs approximately 145 people. It has been publicly traded since 2013.

Enanta Pharmaceuticals

ENTA

Enanta Pharmaceuticals is a biotechnology company utilizing a chemistry-driven approach to discover and develop small molecule drugs for virology and immunology indications.

Market cap

$370.17M+128%

Table of contents

Earnings

Q1 2026 report

May 11, 2026

Revenue$17.2MBeat by $131.7K EPS-$0.45Beat by $0.01

Read the full report

Next report

Aug 10, 2026 (In 1 week)

Revenue estimate$16.8M

EPS estimate-$0.51

Competitors

By market cap

Merck & Co.$322.95B+53.0%

Gilead Sciences$162.05B+15.3%

Regeneron Pharmaceuticals$69.9B+16.0%

Moderna$22.1B+68.3%

Celldex Therapeutics$2.8B+91.5%

Atea Pharmaceuticals, Inc.$385.7M+18.9%

Enanta Pharmaceuticals$370.2M+116%

Invivyd, Inc.$179.7M+78.9%

By revenue growth

Regeneron Pharmaceuticals+5.9%

Gilead Sciences+3.5%

Merck & Co.+2.9%

Moderna-30.0%

Celldex Therapeutics-88.5%

By net margin

Gilead Sciences30.99%+10.2pp

Regeneron Pharmaceuticals29.65%-2.3pp

Merck & Co.13.59%-13.7pp

Moderna-143.55%-37.9pp

Celldex Therapeutics-32,753.58%-30,388pp

Profile

Enanta Pharmaceuticals is a biotechnology company utilizing a chemistry-driven approach to discover and develop small molecule drugs for virology and immunology indications. The company leverages its internal drug discovery engine to create a pipeline of wholly-owned candidates while generating significant royalty revenue from out-licensed hepatitis C therapies. Its core value proposition lies in developing oral, potent, and selective treatments for respiratory infections and chronic inflammatory diseases.

Competitive position

Enanta is a leading innovator in HCV protease inhibitors through its AbbVie partnership and maintains a specialized competitive position in small molecule RSV and oral immunology research.

GeographiesUnited States, European Union, Japan, Global

Customer segmentsPharmaceutical partners, Patients

Business modelResearch and Development, Licensing and Royalties, Drug Discovery

SuppliersContract manufacturing organizations, Raw material suppliers, Clinical research organizations

CustomersAbbVie, OMERS, Wholesale drug distributors, Hospitals and pharmacies

CountryUnited States of America

Listed2013

Employees145.0

CEOJay R. Luly

SectorHealthcare

IndustryBiotechnology

Websiteenanta.com

FilingsSEC EDGAR

Questions, answered.

What is Enanta Pharmaceuticals's market cap?: Enanta Pharmaceuticals (ENTA) has a market capitalization of $370.2M and trades on NASDAQ.
Who are Enanta Pharmaceuticals's competitors?: Enanta Pharmaceuticals's key competitors include Gilead Sciences, Inc., Merck & Co., Inc., Regeneron Pharmaceuticals, Inc., and others. These companies compete in similar markets and product categories.
Who does Enanta Pharmaceuticals partner with?: Enanta Pharmaceuticals's notable partners include AbbVie Inc., OMERS, AstraZeneca, and others.
Where is Enanta Pharmaceuticals headquartered?: Enanta Pharmaceuticals is headquartered in United States of America and employs approximately 145 people. It has been publicly traded since 2013.